ITRMF (Iterum Therapeutics) EPS (Basic): $-0.75 (TTM As of Sep. 2025)


What is Iterum Therapeutics EPS (Basic)?

Iterum Therapeutics ITRMF +18.86% EPS (Basic) is $-0.75 as of Sep. 2025. The stock has 4 warning signs investors should review.

Iterum Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Sep. 2025 was $-0.20. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2025 was $-0.75.

Iterum Therapeutics's EPS (Diluted) for the three months ended in Sep. 2025 was $-0.20. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was $-0.75.

Iterum Therapeutics's EPS without NRI for the three months ended in Sep. 2025 was $-0.19. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2025 was -0.58.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Iterum Therapeutics  (OTCPK:ITRMF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Iterum Therapeutics EPS (Basic) Related Terms

Iterum Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Iterum Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iterum Therapeutics EPS (Basic) Chart

Iterum Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only -29.95 -7.75 -3.35 -2.73 -1.26

Iterum Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.30 -0.25 -0.14 -0.16 -0.20

Iterum Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Iterum Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-24.774-0)/19.699
=-1.26

Iterum Therapeutics's Basic EPS for the quarter that ended in Sep. 2025 is calculated as

Basic EPS (Q: Sep. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-8.979-0)/45.802
=-0.20

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-0.75 mean?
Iterum Therapeutics (ITRMF) has a EPS (Basic) of $-0.75 as of Sep. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Iterum Therapeutics and its competitors.
Is Iterum Therapeutics' EPS (Basic) too high?
Iterum Therapeutics' current EPS (Basic) is $-0.75.
How does Iterum Therapeutics' EPS (Basic) compare to ENSC and PPCB?
Iterum Therapeutics' EPS (Basic) of $-0.75 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Iterum Therapeutics and its competitors. Iterum Therapeutics's current EPS (Basic) is $-0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current EPS (Basic) of $-0.75. The current EPS (Basic) is $-0.75. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current EPS (Basic) is $-0.75 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Iterum Therapeutics Business Description

Address 3 Dublin Landings, North Wall Quay, Dublin 1, Dublin, IRL, D01 C4E0
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.